Bioventus (NYSE:BVS) Price Target Raised to $14.00

Bioventus (NYSE:BVS) had its price objective boosted by equities researchers at Barrington Research from $13.00 to $14.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Barrington Research’s target price indicates a potential upside of 65.09% from the stock’s previous close.

Separately, Craig Hallum increased their price target on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday. Four research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $14.25.

Bioventus Price Performance

Shares of BVS traded down $0.62 during mid-day trading on Friday, hitting $8.48. The company’s stock had a trading volume of 209,449 shares, compared to its average volume of 273,323. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. Bioventus has a 1-year low of $5.81 and a 1-year high of $11.25. The firm has a market capitalization of $701.83 million, a P/E ratio of -13.90 and a beta of 0.78. The firm has a 50-day simple moving average of $8.10 and a 200 day simple moving average of $7.49.

Institutional Trading of Bioventus

Several large investors have recently added to or reduced their stakes in the stock. Marshall Wace LLP boosted its position in shares of Bioventus by 0.4% in the fourth quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock worth $2,149,000 after buying an additional 1,281 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Bioventus by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after acquiring an additional 1,538 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its holdings in Bioventus by 16.2% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock worth $101,000 after acquiring an additional 1,887 shares during the period. Deutsche Bank AG grew its position in Bioventus by 8.2% in the fourth quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock valued at $187,000 after acquiring an additional 1,908 shares in the last quarter. Finally, Covestor Ltd raised its stake in shares of Bioventus by 28.0% during the third quarter. Covestor Ltd now owns 9,951 shares of the company’s stock valued at $67,000 after purchasing an additional 2,176 shares during the period. 62.94% of the stock is currently owned by institutional investors and hedge funds.

More Bioventus News

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Strong Q4 results: Q4 revenue of $157.9M (+2.8% y/y) with organic revenue +10%, GAAP EPS $0.21, non‑GAAP EPS $0.24, and cash from operations of $38.0M (up 97%). This quarter provides near‑term proof of improving profitability and cash generation. Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: FY‑2026 guidance and targets: management outlined a $600M–$610M 2026 sales target and issued EPS guidance of $0.73–$0.77, slightly above consensus — signaling confidence in growth drivers (PNS, PRP, ultrasonics) and margin expansion. Bioventus outlines $600M–$610M 2026 sales target with accelerated investment in PNS, PRP, and
• Positive Sentiment: Analyst upgrade: Craig Hallum raised its price target to $16 and maintains a “buy” rating, implying material upside from current levels and adding buy‑side validation. Benzinga
• Neutral Sentiment: Investor materials available: full earnings call transcript and presentation published (useful for digging into product‑level trends and 2026 investment priorities). Bioventus (BVS) Q4 2025 Earnings Call Transcript Bioventus Inc. 2025 Q4 – Results – Earnings Call Presentation
• Negative Sentiment: Short‑term pullback/volatility: shares had jumped after the earnings beat, and today’s decline likely reflects profit‑taking and short‑term rotation rather than a change to the company’s fundamentals.
• Negative Sentiment: Balance‑sheet and valuation considerations: investors may be weighing a modest liquidity profile (quick ratio ~0.99), relatively high leverage (debt‑to‑equity ~1.85) and mixed multi‑quarter profitability metrics when setting near‑term expectations.

About Bioventus

Bioventus, Inc (NYSE: BVS) is a global medical technology company focused on providing innovative therapeutic solutions to enhance patient care in musculoskeletal health. The company develops, manufactures, and markets a range of products designed to promote bone healing, support joint health, and relieve pain non-invasively. Bioventus leverages biologic and biophysical approaches to deliver effective therapies that aim to accelerate recovery times and improve overall patient outcomes.

Bioventus’s product portfolio includes its flagship EXOGEN® Bone Healing System, an ultrasound-based device indicated for non-union fractures and fracture healing enhancement.